©The Author(s) 2025.
World J Gastroenterol. Dec 14, 2025; 31(46): 113172
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.113172
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.113172
Table 1 Univariate analysis of biomarker intensities: Comparison of inflammatory bowel disease vs non-inflammatory bowel disease patients, mean ± SD
| Biomarker | IBD (n = 155) | Non-IBD (n = 91) | P value |
| CCL2 | 101 ± 42.9 | 108 ± 43.7 | 0.239 |
| CCL5 | 1650 ± 1010 | 1710 ± 665 | 0.526 |
| CCL7 | 249 ± 135 | 244 ± 120 | 0.761 |
| IL-8 | 27.1 ± 151 | 8.93 ± 4.63 | 0.138 |
| TSLP | 269 ± 123 | 265 ± 132 | 0.812 |
| CCL3 | 45.6 ± 15.7 | 44.0 ± 13.1 | 0.409 |
| CXCL1 | 347 ± 289 | 306 ± 275 | 0.267 |
| CXCL2 | 200 ± 197 | 196 ± 225 | 0.892 |
| CXCL9 | 3980 ± 3250 | 1440 ± 1460 | < 0.001 |
| IL-18 | 169 ± 187 | 134 ± 216 | 0.204 |
| IL-22 | 52.8 ± 163 | 31.9 ± 13.6 | 0.113 |
| TARC | 326 ± 461 | 331 ± 241 | 0.913 |
- Citation: Eindor-Abarbanel A, Tsai K, Sandhu A, Vallance B, Jacobson K. Serum C-X-C motif chemokine ligand 9, interleukin 8, and interleukin 22 as key biomarkers in pediatric inflammatory bowel disease. World J Gastroenterol 2025; 31(46): 113172
- URL: https://www.wjgnet.com/1007-9327/full/v31/i46/113172.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i46.113172